Notably, the severity of fatal organ involvement varies across anti-CTLA-4 and anti-PD-1/PD-L1 interventions, with colitis being the most commonly observed in the former and neurotoxicity, hepatitis, and pneumonitis being recorded in the latter. The gene discussed is CTLA4; the disease is hepatitis A virus infection.